Moderna Therapeutics
$20Bmarket cap
// OVERVIEW
Moderna built a $190 billion market cap by proving mRNA vaccine technology works in a pandemic — then lost 89% of it proving the technology does not work as a sustainable revenue model. The company that convinced investors in 2018 that messenger RNA would revolutionize medicine delivered exactly one commercially successful product, collected $36 billion in COVID-19 vaccine revenue between 2021-2022, and now faces the $20 billion question of whether any of its 48 pipeline candidates can generate profit without a global health emergency creating guaranteed demand.
// HQ
Cambridge, United States
// STATUS
PUBLIC
// FOUNDED
2010
// TIER
The Decacorns · $10B – $99B
// PRIMARY SECTOR
biotechnology
// FOUNDERS
// FUNDING ROUNDS
// SECTORS SERVED
// TECHNOLOGY
Moderna's platform synthesizes messenger RNA sequences that instruct human cells to produce specific proteins — in theory enabling rapid vaccine development for any pathogen and therapeutic protein replacement for genetic diseases. The technology worked spectacularly for COVID-19 because the spike protein target was simple, the regulatory pathway was compressed, and governments pre-purchased billions of doses before efficacy was proven. It has not yet worked commercially for anything else because most diseases require more complex protein interactions than a single mRNA sequence can encode, and because manufacturing costs remain 10-50x higher than traditional small molecule drugs for equivalent therapeutic effect.
// WOWLS ASSESSMENT
Moderna generated $19.3 billion in revenue in 2022 and $6.8 billion in 2023 — a 65% year-over-year collapse that accelerated to $3.1 billion in 2024. The company is now burning approximately $4 billion annually on R&D for a pipeline that includes a respiratory syncytial virus vaccine, a cytomegalovirus vaccine, and 46 other candidates in various trial stages. None have reached profitability and the RSV vaccine — the most advanced non-COVID product — posted $155 million in sales in its first full year while competitors' RSV vaccines took comparable market share. Wall Street valued Moderna at $190 billion in August 2021 when COVID vaccine revenue looked permanent. The current $20 billion market cap implies the market believes either the pipeline will produce 2-3 blockbuster products within 5 years or the company will be acquired before the cash runs out. Both scenarios require Moderna to solve the fundamental economics problem that mRNA remains structurally more expensive to manufacture than the small molecules and biologics it is attempting to replace.
// WHY WOWLS HUNTS THIS
A $20 billion market cap built on $36 billion in pandemic revenue that will never recur and a pipeline that has yet to produce a single profitable non-COVID product. The company burns $4 billion annually and the clock is running.
// VALUATION NOTE
Market cap declined from $190B peak (Aug 2021) to current $20B. COVID vaccine revenue was $19.3B (2022), $6.8B (2023), $3.1B (2024). Company guidance projects continued revenue decline through 2025.
VERDICT: TERMINAL HYPE — MODERNA LOST $170 BILLION IN MARKET CAP IN 3 YEARS BECAUSE THE MARKET DISCOVERED THAT SOLVING ONE DISEASE WITH GUARANTEED GOVERNMENT DEMAND DOES NOT VALIDATE A PLATFORM FOR SOLVING 48 OTHERS WITHOUT IT
// PACK DEBATE
// PACK DEBATE — be the first to weigh in
Google account required — no spam, no nonsense
// LOADING INTEL…
// BROADCAST INTEL
// SIMILAR TARGETS
// INTEL UPDATED: MAY 2026
// INTELLIGENCE DISCLAIMER: Assessments represent editorial opinion based on publicly available data including filings, press reports, and market data as of the date shown. Valuations are approximate. Not financial or investment advice.
// FULL NETWORK ACCESS
🚀 Founder Briefing: Instantly sort investors by Sector, Stage, & Round — direct links to websites for all 1,030 unicorns & backing VCs included.
Don't just track Moderna Therapeutics.
Master the entire 1,030 unicorn company intelligence network.
Stop analyzing tech monopolies one page at a time. Instantly filter, sort, and isolate the exact venture capital firms, angel investors, and corporate funds backing your specific market vertical. Find investors that fit your sector and deploy your pitch with direct outbound links to every target asset in the database — 1,030 targets total.
Acquire Intel →// 5 TIERS · PAYPAL SECURED
// ENGAGE THE FULL ARSENAL
Done reading on Moderna Therapeutics?
Unlock the entire 1,030-company hitlist and 1,030 investor contacts.
Full structural breakdowns. Founder dossiers. VC outreach data. Threat-level intel updated continuously.
→ Deploy 5-Tier Order Form// ARBAN · ZUUN · MINGHAN · TUMEN · KHAN